Background {#Sec1}
==========

There is evidence that the use of multiple medications has been rising over the past years, especially among older people \[[@CR1]\]. Platelet aggregation inhibitors (PAI) constitute some of the most frequently prescribed drugs among people aged ≥65 \[[@CR2], [@CR3]\]. They are indicated in the prevention of cardiovascular disease, during and after myocardial infarction or acute coronary syndrome, during and after angioplasty and stenting, in the prevention of stroke and transient ischaemic attacks (TIA), and in the prevention of peripheral artery occlusive disease \[[@CR4]--[@CR6]\]. The pharmacological mechanism of action of PAI is the inhibition of thrombocyte activation and/or impeding aggregation. The treatment goal is preventing thrombotic complications \[[@CR7]\]. However, an undesirable effect of this platelet inhibition is an increase in the risk of bleeding \[[@CR8]\].

Despite the benefit of reducing cardiovascular events, several studies show that PAI are frequently associated with hospital admission due to adverse drug events \[[@CR9]--[@CR12]\]. Some of these adverse drug events could be avoided, for instance by an increased monitoring of the use of drugs and regular medication reviews \[[@CR9]--[@CR11]\]. In the case of acetylsalicylic acid (ASA), secondary prophylaxis with Helicobacter pylori eradication and proton pump inhibitors reduces the risk of gastrointestinal bleeding \[[@CR9]\].

The use of PAI has been questioned in older people due to a higher risk of adverse events compared to younger, healthier adults \[[@CR13], [@CR14]\]. This higher risk is attributable to changes in pharmacokinetics and pharmacodynamics and a higher risk of drug interactions in older people \[[@CR15]\].

Evidence regarding the risks and benefits of antiplatelet drugs in older people is scarce, as most studies focus on younger patients with fewer co-morbidities \[[@CR16]\]. Existing guidelines usually do not adapt for old age and multimorbidity \[[@CR17]\]. Hence, the balance between risks and benefits of PAI in the management of cerebrovascular disease, peripheral artery occlusive disease, and coronary disease in older adults with multimorbidity is not clear \[[@CR12]\]. We therefore set out to systematically review the available evidence regarding the use of PAI in older and multimorbid people.

The objectives of this Systematic Review (SR) areTo identify the risks and benefits of the use of PAI in the treatment or prevention of cerebrovascular disease, peripheral artery occlusive disease, and coronary disease in older adults.To develop recommendations which will enable physicians to stop the use of PAI in the treatment or prevention of cerebrovascular disease, peripheral artery occlusive disease, and coronary disease in older adults based on current best evidence.

The developed stop-recommendations will be incorporated in an electronic decision support tool for general practitioners within the EU-Project PRIMA-eDS (Polypharmacy in chronic diseases: Reduction of Inappropriate Medication and Adverse drug events in older populations by electronic Decision Support) \[[@CR18]\].

Methods {#Sec2}
=======

A SR was performed in accordance with the methodology described earlier \[[@CR19]\] following a specific study protocol (available from the authors upon request). We will report on the results narratively.

Search strategy {#Sec3}
---------------

As described in the publication of our methodology \[[@CR19]\], we employed a step-wise approach that consisted of four searches, of which the consecutive one was only conducted when the prior one did not lead to recent and high quality results. Search 1 was targeted at SR and meta-analyses (MA) in the Cochrane Database of Systematic Reviews (OVID interface, 2005 onwards) and Database of Abstracts or Reviews of Effects (DARE, OVID interface, 1991 onwards). Search 2 was also directed at SR and MA, but extended to MEDLINE (OVID interface, 1946 onwards), EMBASE (OVID interface, 1974 onwards), Health Technology Assessment (HTA, OVID interface 2001 onwards), and International Pharmaceutical Abstracts (IPA, OVID interface 1970 onwards). Search 3a was performed to find single studies (randomized controlled trials (RCT) and observational studies (OS) from SR and MA not included in searches 1 and 2 due to not meeting our inclusion criteria but containing eligible studies. Search 3b looked for RCT and OS in MEDLINE, EMBASE, HTA and IPA.

For this SR, searches 1 and 2 were performed in December 8th, 2015. The search string (see additional file [1](#MOESM1){ref-type="media"}) was developed with the help of a PICOS (population, intervention, comparison, outcomes and study design) framework. In search 3a, we identified eligible randomised controlled trials and OS from SR and MA, which themselves were not eligible for inclusion in our review (mainly because they were not focussed at older people). In parallel to the study selection of searches 1 and 2, we prepared a list of references to be checked in search 3a. Search 3b was considered as not being necessary because the SR and MA retrieved covered all eligible studies (see results) and we did not expect to find any additional eligible studies. In addition to database searches, all the references of the included studies were checked to obtain a comprehensive list of studies. Study protocols were collected to consider future updates of the SR. We also obtained articles from other sources (e.g. hand search).

Study selection {#Sec4}
---------------

Two reviewers (AR, MM) independently screened titles and abstracts. When the abstracts seemed to meet the inclusion criteria, full texts were retrieved and assessed for inclusion. When needed, a third reviewer (ARG) was consulted to solve any disagreements. At the end of each search stage, the quality and completeness of the obtained studies were assessed and it was decided whether or not to proceed to the next stage of the search.

Inclusion and exclusion criteria {#Sec5}
--------------------------------

Articles were assessed for inclusion regarding the type of study, age of participants, type of intervention, and clinical relevance of the outcomes.

The following articles were excluded: editorials, opinion papers, case reports, case series, narrative reviews, letters, qualitative studies, and OS which do not provide information regarding our outcomes. Articles not focussing on patient relevant outcomes were also excluded.

Table [1](#Tab1){ref-type="table"} displays details of the inclusion and exclusion criteria.Table 1Detailed inclusion and exclusion criteria regarding the type of study, age, intervention and outcomesCriteriaInclusionExclusionType of studySR &MARCTOSeditorials, opinion papers, case reports, case series, narrative reviews, letters, qualitative studies and observational studies which do not provide information of interest regarding adverse eventsAge of participantsmean or median age ≥ 65 years, or subgroup analysis ≥ 65 years≥ 80% of participants ≥ 65 years or a subgroup analysis ≥ 65 yearsType of interventionefficacy and/or safety of PAI as monotherapy or in combination with any other drug for the treatment or prevention of cerebral infarction, transient ischaemic attacks, peripheral artery occlusive disease and coronary disease or one of these indications versus placebo, no treatment, other drugs or a non-pharmacological interventionfocus on acute conditions (like exclusively acute treatment of myocardial infarction during the first hours)Clinically relevant outcomesquality of life, mortality, life expectancy, hospitalization, cognitive impairment or cognitive status, functional impairment or functional status, cardiovascular event including stroke, renal failure, composite end points including any of the above (extraction of individual outcomes will be done if reported by original studies), adverse drug event, bleedingsurrogate endpoints (like laboratory measurements or blood pressure)*MA* meta-analysis, *OS* observational study, *RCT* randomised controlled trial, *SR* systematic review Table 2Characteristics of included SR/MAReferenceType of studyAimPopulation (number of studies, participants, mean age)TreatmentOutcomesAguilar 2005 \[[@CR49]\]SRTo assess the efficacy and safety of long-term APT for primary prevention in stroke of patients with chronic non-valvular AF.Studies *n* = 5, 1965 participants, mean age 70 yearsWarfarin INR 2.8--4.2 vs ASA 75 mg/d vs placebo, ASA 125 mg/d vs placebo, warfarin INR 2--4.5 vs control and ASA 325 mg/d vs placeboAll strokes, ischaemic strokes, all disabling or fatal stroke, myocardial infarction, systemic emboli, all intracranial haemorrhage, major extracranial haemorrhage, vascular death and the composite of all stroke, myocardial infarction, vascular death and all-cause mortalityAguilar 2007 \[[@CR30]\]SRTo characterize the relative effect of long-term oral anticoagulant treatment compared with antiplatelet therapy on major vascular events in patients with non-valvular AF and no history of stroke or TIA.Studies *n* = 7, 9598 participants, mean age 64--75 yearsClopidogrel 75 mg/d + ASA 75-100 mg/d vs warfarin INR 2--3, ASA 75 mg/d vs warfarin INR 2.8--4.2 vs placebo, ASA 300 mg/d vs fixed-dose warfarin vs fixed-dose warfarin + ASA 300 mg/d vs adjusted-dose warfarin INR 2--3, ASA 100 mg/d vs fixed-dose VKA vs adjusted-dose VKA INR 2.6--3.5, triflusal 600 mg/d vs adjusted-dose VKA INR 2--3, ASA 150 mg/d vs warfarin INR 2.5--3.5 vs low-dose warfarin INR 1.1--1.6, ASA 325 mg/d vs warfarin INR 2--4.5, ASA 325 mg/d vs adjusted-dose warfarin INR 2--4.5Primary outcome: all strokes; Secondary outcomes: ischaemic strokes, all disabling or fatal strokes, myocardial infarction, systemic emboli, all intracranial haemorrhages, major extracranial haemorrhages, vascular death, all-cause mortalityAndersen 2008 \[[@CR43]\]MATo evaluate the efficacy of warfarin in preventing systemic embolism (embolism to limbs or viscera) in patients with AFStudies *n* = 15, 16,058 participants, mean age 63.3--81.5 yearsWarfarin vs placebo vs ASA 75 mg/d, warfarin vs placebo, warfarin vs ASA 325 mg/d, warfarin vs low-dose warfarin (INR 1.2--1.5) + ASA 325 mg/d, warfarin vs indobufen 200 mg/d, warfarin vs low-dose warfarin 1.25 mg/d, warfarin vs low-dose warfarin 1.25 mg/d vs low-dose warfarin + ASA 300 mg/d vs ASA 300 mg/d, warfarin vs ASA 150 mg/d vs low-dose warfarin (INR 1.1--1.6), warfarin vs low-dose warfarin (INR 1.5--2.1), warfarin vs ASA 150-160 mg/d, warfarin vs clopidogrel 75 mg/d + ASA 75-100 mg/d, warfarin vs ASA 300 mg/d, warfarin vs ASA 75 mg/dSystemic embolism and major bleedingAssiri 2013 \[[@CR44]\]MAA mixed treatment comparison meta-analysis to evaluate direct and indirect treatment data including ASA, warfarin apixaban, dabigatran, edoxaban and rivaroxaban for the prevention of primary or secondary stroke in patients with AFStudies *n* = 21, 80,906 participants, mean age 71 yearsASA vs warfarin vs placebo, ASA vs warfarin, warfarin vs placebo, ASA vs placebo, ASA + warfarin vs placebo, ASA + clopidogrel vs warfarin, dabigatran vs warfarin, ASA vs ASA + clopidogrel, edoxaban vs warfarin, apixaban vs warfarin, rivaroxaban vs warfarinAny stroke or embolism, all-stroke, ischemic stroke, systemic embolism, vascular death, all-cause mortality, major and non-major bleeding, and intra-cranial haemorrhageBaigent 2009 \[[@CR28]\]MATo assess the benefits and risks in primary prevention; Identify risk factors for various outcomes in people in the primary prevention trialsStudies *n* = 6 primary prevention, 16 secondary prevention, 112,000 participants, subgroup ≥ 65 yearsASA 500 mg/d, ASA 325 mg/d vs placebo, ASA 75 mg/d vs warfarin vs placebo, ASA 75 mg/d vs placebo, ASA 100 mg/d vs control, ASA 100 mg/d vs placeboVascular events (myocardial infarction, stroke, death from vascular cause), major coronary event, any stroke, death from any cause, major extracranial bleedingCameron 2014 \[[@CR46]\]NMATo examine the comparative efficacy and safety of antithrombotic treatments (apixaban, dabigatran, edoxaban, rivaroxaban and VKA at a standard adjusted dose (target international normalised ratio 2.0--3.0), ASA, ASA and clopidogrel) for non-valvular atrial fibrillation and among subpopulationsStudies *n* = 16, 82,314 participants, mean age 62--83, subgroup-analysis age ≥ 75 yearsDabigatran 150 mg twice daily vs dabigatran 110 mg twice daily vs adjusted-dose VKA, edoxaban 60 mg/d vs edoxaban 30 mg/d vs adjusted-dose VKA, ASA 100 mg/d + clopidogrel 75 mg/d vs adjusted-dose VKA, ASA 100 mg/d vs placebo, ASA 100 mg/d vs adjusted-dose VKA, adjusted-dose VKA vs placebo, ASA 100-300 mg/d vs placebo, ASA 100-300 mg/d vs adjusted-dose VKA, rivaroxaban 20 mg/d vs adjusted-dose VKA, apixaban 5 mg twice daily vs adjusted-dose VKA, dabigatran 150 mg twice daily 100-300 mg ASA vs adjusted-dose VKA, apixaban 2.5 mg twice daily vs apixaban 5 mg twice daily vs adjusted-dose VKAPrimary outcomes: all-cause stroke, systemic embolism, major bleedingCooper 2006 \[[@CR42]\]NMATo identify different stroke prevention treatments for atrial fibrillation assessed in randomized controlled trials and to compare them within a single evidence synthesis frameworkStudies *n* = 19, 17,833 participants, mean age 64--80.5 yearsWarfarin INR 2--3 vs ximelegatran 72 mg/d, warfarin 1.25 mg/d + ASA 75 mg/d vs control, warfarin INR 2.2--3.5 vs warfarin INR 1.5--2.1, warfarin INR 1.2--1.5 vs control, warfarin prothrombin-time 1.2--1.5 vs placebo, warfarin INR 2--3 vs placebo, warfarin vs ASA 300 mg/d vs placebo, ASA 325 mg/d vs warfarin vs placebo, warfarin 1.25 mg/d vs warfarin 1.25 mg/d + ASA 300 mg/d vs ASA 300 mg/d vs warfarin INR 2.3, coumarin INR 2.5--3.5 vs coumarin INR 1.1--1.6 vs ASA 150 mg/d, indobufen 100 or 200 mg/d vs warfarin INR 2--3.5, warfarin INR 1.25 mg/d vs warfarin INR 2--3, warfarin INR 1.2--1.5 + ASA 325 mg/d vs warfarin INR 2--3, ASA 125 mg/d vs ASA 125 mg/d on alternate days vs controlPrimary outcome: ischaemic stroke, major or fatal bleedingColeman 2012 \[[@CR56]\]MATo identify the propensity difference between various AP and anticoagulation for stroke prevention in patients with AF to cause MGIBStudies *n* = 16, 42,983 participants, mean age 65--75 yearsClopidogrel 75 mg/d + ASA 75-100 mg/d, ASA 75-100 mg/d vs dabigatran 110 mg BID vs dabigatran 150 mg BID vs adjusted-dose warfarin, ASA 150-200 mg/d vs control, adjusted-dose warfarin vs ximelagatran 36 mg BID, triflusal 600 mg/d vs adjusted-dose VKA vs adjusted-dose VKA + ASA 100 mg/d, adjusted-dose VKA + placebo vs adjusted-dose VKA + ASA 100 mg/d, adjusted-dose warfarin vs low-dose warfarin, adjusted-dose VKA vs low-dose VKA vs ASA 150 mg/d, adjusted-dose warfarin vs low-dose warfarin vs ASA 300 mg/d vs low-dose warfarin + ASA 300 mg/d, indobufen 200 mg BID vs adjusted-dose warfarin, low-dose warfarin + ASA 325 mg/d, adjusted-dose warfarin (INR 2--3 or 2--4.5) vs ASA 325 mg/d, adjusted-dose VKA vs ASA 300 mg/d vs placebo, adjusted-dose warfarin vs placebo, warfarin vs no treatment, adjusted-dose warfarin vs ASA 75 mg/d vs placeboMajor gastrointestinal bleedingConnolly 2013 \[[@CR61]\]MATo characterize the risk of subdural hematoma associated with antiplatelet therapyStudies *n* = 9, 97,254 participants, mean age 57 years, subgroup ≥ 70 yearsASA 325 mg/d vs placebo, ASA 75 mg/d vs placebo, ASA 150-200 mg/d vs control, ASA 81-100 mg/d vs control, ASA 325 mg every other day vs placebo, ASA 50 mg/d + dipyridamol 400 mg/d vs placebo, ASA 75 mg/d vs placebo, ASA 100 mg every other day vs placebo, ASA 100 mg/d vs placeboSubdural hematomas, intracerebral haemorrhageDogliotti 2014 \[[@CR41]\]NMATo synthesise the evidence from trials using a multiple treatment comparison methods thereby permitting a broader comparison across multiple therapiesStudies *n* = 20, 79,808 participants, mean age 64--83Adjusted-dose warfarin vs ASA vs placebo, adjusted-dose warfarin vs placebo, adjusted-dose VKA vs ASA vs placebo, adjusted-dose warfarin vs ASA, adjusted-dose coumarin vs ASA, ASA vs no treatment, adjusted-dose warfarin vs ASA + clopidogrel, ASA vs no treatment, clopidogrel + ASA vs ASA, adjusted-dose warfarin vs ASA, dabigatran 110 mg twice daily vs dabigatran 150 mg twice daily vs adjusted-dose warfarin, apixaban vs adjusted-dose warfarin, apixaban vs ASA, adjusted-dose warfarin vs rivaroxabanPrimary outcomes: stroke, composite of ischaemic stroke or systemic embolism, death from any cause, major bleedingGandhi 2015 \[[@CR54]\]MATo compare Dual-antiplatelet Therapy to Mono-antiplatelet Therapy after Transcatheter Aortic Valve ImplantationStudies *n* = 4, 640 participants, mean age 82.2 yearsASA 80 mg/d + clopidogrel 75 mg/d or ticlopidin 500 mg BID vs ASA 75-160 mg/d, ASA 75 mg/d + clopidogrel 75 mg/d (300 mg loading-dose) vs ASA 75 mg/d or clopidogrel 75 mg/d, ASA 75 mg/d + clopidogrel 75 mg/d (300 mg loading-dose) vs ASA 75 mg/d (300 mg loading-dose), ASA 100 mg/d + clopidogrel 75 mg/d (300 mg loading-dose) vs ASA 100 mg/dPrimary outcome: combined end point of 30-day stroke, spontaneous myocardial infarction, all-cause-mortality, combined lethal and major bleeding. Secondary outcomes: 30-day major stroke, 30-day spontaneous myocardial infarction, 30-day all-cause mortality, 30-day combined lethal and major bleeding, 6-months major stroke, 6-months myocardial infarction, 6-months all-cause mortality, 6-months combined lethal and major bleedingHalkes 2008 \[[@CR56]\]MATo study the effect of combination therapy with ASA and dipyridamole (A + D) over ASAalone in secondary prevention after transient ischemic attack or minor stroke of presumed arterial origin and to perform subgroup analyses to identify patients that might benefit most from secondary prevention with A + DStudies *n* = 5, 7612 participants, mean age 65 yearsASA + dipyridamol vs ASA, ASA + dipyridamol vs ASA vs dipyridamol vs placebo. ASA ranged from 50 mg/d-990 mg/d. Dipyridamol ranged from 150 mg/d-400 mg/d.Death from all vascular causes, nonfatal stroke, nonfatal myocardial infarctionHart 2007 \[[@CR40]\]MATo characterize the efficacy and safety of antithrombotic agents for stroke prevention in patients who have atrial fibrillation, adding 13 recent randomized trials to a previous meta-analysisStudies *n* = 29, 28,044 participants, mean age 71 yearsWarfarin vs ASA vs placebo, warfarin vs control, warfarin vs placebo, LMWH vs control, warfarin vs ASA, warfarin vs low-dose warfarin + ASA, warfarin vs indobufen, ASA vs dipyridamol vs ASA + dipyridamol vs placebo, warfarin vs low-dose warfarin vs ASA vs low-dose warfarin + ASA, warfarin vs low-dose warfarin, warfarin vs low-dose warfarin vs ASA, ASA daily vs ASA every other day vs control, ASA vs placebo, warfarin vs warfarin, fluindione vs fluindione + ASA, ximelagatran vs warfarin, low-dose warfarin + ASA vs control, triflusal vs VKA vs triflusal + VKA, ximelagatran vs warfarin, ASA vs control, warfarin vs clopidogrel + ASA, dabigatran vs dabigatran +ASA vs warfarinAll strokes, ischaemic stroke, intracranial haemorrhage, all-cause mortality, major extracranial haemorrhageHart 1999 \[[@CR39]\]MATo analyse the increased risk of intracranial haemorrhage when ASA is combined with WarfarinStudies *n* = 16, 9874 participants, mean age 69--71 yearsWarfarin INR 2.8--4.2 vs ASA 75 mg/d, ASA 300 mg/d vs warfarin INR 2--3, warfarin vs placebo + ASA 325 mg/d vs Placebo, ASA 325 mg/d vs warfarin 2--4.5, warfarin INR 1.2--1.5 + ASA 325 mg/d vs warfarin INR 2--3, warfarin INR 1.2--1.5 vs Control, warfarin vs placebo, warfarin 1.2--1.5 vs placebo, OAC INR 3--4.5 vs ASA 300 mg/d vs placebo, indobufen 100-200 mg vs warfarin INR 2--3.5, warfarin fixed-dose 1.25 mg/d vs warfarin INR 2--3, ASA 150 mg/d vs warfarin INR 2.5--3.5, LMWH vs control, ASA 125 mg/d vs ASA 125 mg/d on alternate days vs control, ASA 600 mg/d vs ASA 300 mg/d vs placeboAll strokes, ischaemic stroke, intracranial haemorrhage, all-cause mortality, major extracranial bleedingHe 1998 (JAMA) \[[@CR29]\]MATo estimate the risk of haemorrhagic stroke associated with ASA treatmentStudies *n* = 16, 55,462 participants, mean age 63.7 years, subgroup ≥64 yearsASA 1200 mg/d vs placebo, ASA 1300 mg/d vs placebo, ASA 900 mg/d vs placebo, ASA 1000 mg vs ASA 1000 mg + 325 mg dipyridamol, ASA 1000 mg/d vs placebo, ASA 1500 mg/d vs placebo, ASA 160 mg/d vs streptokinase vs both vs placebo, ASA 500 mg/d vs placebo, ASA 325 mg/d vs placebo, ASA 75 mg/d vs warfarin vs placebo, ASA 325 mg/d vs warfarin vs placebo, ASA 75 mg/d vs placebo, ASA 300 mg/d vs placeboPrimary outcome: stroke. Secondary outcomes: myocardial infarction, cardiovascular disease mortality, all-cause mortalityLeonardi-Bee 2005 \[[@CR55]\]MATo assess whether dipyridamole, given with or without ASA, reduced stroke in patients with previous ischemic cerebrovascular diseaseStudies *n* = 7, 11,459 participants, mean age 65.4, subgroup age ≥ 65 yearsDipyridamol 100-200 mg/d vs control, dipyirdamol 20 mg/d + ASA 300 mg/d vs ASA 300 mg/d vs control, dipyridamol 75 mg/d + ASA 330 mg/d vs ASA 330 mg/d vs control, dipyridamol 75 mg/d + ASA 325 mg/d vs ASA 325 mg/d, dipyridamol 75 mg/d vs dipyridamol 75 mg/d + ASA 300 mg/d vs ASA 300 mg/d, dipyridamol 100 mg/d + ASA 50 mg/d vs dipyridamol 100 mg/d, dipyridamol 75 mg/d + ASA 330 mg/d vs control, dipyridamol 200 mg/d + ASA 25 mg/d vs ASA 25 mg/d vs dipyridamol 200 mg/d vs controlPrimary outcome: composite of death from all vascular causes, fatal stroke, non-fatal myocardial infarction. Secondary outcomes: composite of death from all vascular causes or non-fatal stroke, all death, death from vascular causes, fatal and non-fatal stroke, fatal and non-fatal myocardial infarctionLin 2015 \[[@CR63]\]NMATo summarize and compare clinical and safety outcomes of oral antithrombotics for stroke prevention in AF in younger (65--74 years) and older (≥ 75 years) elderlyStudies *n* = 49, 897,748 participants, mean age 71 years, subgroup age ≥ 75 yearsDabigatran 150 mg vs dabigatran 110 mg vs warfarin, dabigatran 150 mg vs warfarin, rivaroxaban vs warfarin, apixaban vs warfarin, edoxaban vs warfarin, ASA vs warfarin, warfarin vs ASA + clopidogrel, warfarin vs ASA vs control, warfarin vs control, ASA vs control, apixaban vs ASA, ASA + clopidogrel vs ASA, warfarin vs ASA, warfarin vs ASA vs control, dabigatran 150 mg vs warfarin vs rivaroxaban, dabigatran vs rivaroxaban, dabigatran 150 mg vs dabigatran 110 mg vs rivaroxaban vs warfarin, dabigatran vs rivaroxaban vs warfarin, dabigatran vs warfarin, rivaroxaban vs warfarin, warfarin vs ASA vs ASA + clopidogrelPrimary outcomes: stroke, systemic embolism, major bleeding. Secondary outcomes: ischaemic stroke, all-cause mortality, intracranial bleeding, gastrointestinal bleedingLip 2006 \[[@CR45]\]MATo compare the effectiveness of ASA, warfarin, and ximelagatran as thromboprophylaxis in patients with non-valvular atrial fibrillationStudies *n* = 13, 14,423 participants, mean age 64--80 yearsWarfarin INR 2.8--4.2 vs ASA 75 mg/d vs placebo, warfarin INR 1.5--2.7 vs placebo, warfarin INR 2--3 vs placebo, warfarin prothrombin time 1.3--1.8 vs placebo, warfarin INR 1.4--2.8 vs placebo, warfarin 2.5--4.0 vs placebo, warfarin INR 2.7 vs ASA 325 mg/d, warfarin INR 2.6 vs ASA 325 mg/d, warfarin INR 2--3 vs fixed low-dose warfarin + ASA 325 mg/d, warfarin INR 2--3 vs ASA 300 mg/d vs fixed low-dose warfarin vs fixed low-dose warfarin + ASA 300 mg/d, warfarin INR 2.5--3.5 vs ASA 150 mg/d vs fixed low-dose warfarin, warfarin INR 2--3 vs ASA 75-300 mg/d, warfarin INR 2--3 vs ximelagatran 72 mg/d, warfarin INR 2--3 vs ximelagatran 72 mg/dIschaemic stroke, systemic embolism, mortality, haemorrhageSegal 2000 \[[@CR38]\]MATo appropriate use of drugs to prevent thromboembolism in patients with AF involves comparing the patient's risk of stroke and risk of haemorrhage. Summarize the evidence regarding the efficacy of the medicamentsStudies *n* = 11, 8690 participants, mean age 66--80 yearsWarfarin vs placebo, ASA 325 mg/d vs warfarin, warfarin vs ASA 325 mg/d + low-dose warfarin, ASA 75 mg/d vs warfarin vs placebo, warfarin vs ASA 300 mg/d vs ASA 300 mg/d + low-dose warfarin, warfarin vs ASA 300 mg/d vs placebo, warfarin vs indobufen 200 mg, anti-factor Xa vs placeboStroke, major haemorrhage, minor haemorrhage, total mortalityTaylor 2001 \[[@CR37]\]MATo examine the benefits and risks of long term anticoagulation (warfarin) compared with antiplatelet treatment (ASA/indoprofen) in patients with non­rheumatic atrial fibrillationStudies *n* = 6, 3298 participants, mean age 64--80 yearsASA 75 mg/d vs warfarin INR 2.8--4.2, ASA 325 mg/d vs warfarin INR 2--4.5, ASA 300 mg/d vs warfarin INR 2--3, indoprofen 400 mg/d vs warfarin INR 2--3.5, ASA 150 mg/d vs warfarin INR 2.5--3.5Fatal and non-fatal cardiovascular events, fatal and major non-fatal bleeding eventsWarkentin 2012 \[[@CR57]\]MATo provide a pooled estimate of the bleeding risk from randomized controlled trials RCTs comparing warfarin and ASA at the dose ranges recommended in evidencebased guidelinesStudies *n* = 8, 2948 participants, mean age 62--83 years, subgroup age ≥ 70 yearsASA 80 mg/d vs warfarin INR 2--2.5, ASA 100 mg/d vs warfarin INR 2--3, ASA 300 mg/d vs warfarin INR 2--3, ASA 75 mg/d vs warfarin INR 2--3, ASA 325 mg/d vs warfarin INR 2--3, ASA 162 mg/d vs warfarin INR 2--3.5Major bleedingZhou 2012 \[[@CR52]\]MATo evaluate the benefits and harms of combined ASA and clopidogrel therapy on major cardiovascular outcomesStudies *n* = 7, 48,248 participants, mean age 61.7--71 yearsClopidogrel 75 mg/d + ASA 75-325 mg/d vs ASA 75-325 mg/d, clopidogrel 75 mg/d + ASA 100-200 mg/d vs ASA 100-200 mg/d, clopidogrel 75 mg/d + ASA 75-100 mg/d vs ASA 75-100 mg/d, clopidogrel 75 mg/d + ASA 162 mg/d vs ASA 162 mg/d, clopidogrel 75 mg/d + ASA 75-162 mg/d vs ASA 75-162 mg/d, clopidogrel 75 mg/d + ASA 81-325 mg/d vs ASA 81-325 mg/d, clopidogrel 75 mg/d + ASA 75 mg/d vs clopidogrel 75 mg/dMajor cardiovascular events, myocardial infarction, stroke, mortality, major bleeding events, other adverse reaction*AF* atrial fibrillation, *APT* Anti-platelet therapy, *ASA* acetylsalicylic acid, *BID* twice a day, *INR* international normalized ratio, *LMWH* low molecular weight heparin, *MA* meta-analysis, *MGIP* major gastrointestinal bleeding, *NMA* network-meta-analysis, *OAC* oral anticoagulation, *RCT* randomized controlled trials, *SR* systematic review, *TIA* transient ischemic attack, *VKA* Vitamin K Antagonist Table 3Characteristics of included RCTReferenceType of studyAimTreatmentSample size and amount of older participantsFollow-upOutcomesBritton 1987 \[[@CR58]\]RCTTo study the effectiveness of high-dose ASA after cerebral infarctionASA 1.5 g/d vs placebo*N* = 505, mean age 68 years2 yearsPrimary outcomes: Recurrent stroke or death. Secondary outcomes: myocardial infarction, TIADiener 2004 \[[@CR53]\]RCTTo assess whether addition of ASA to clopidogrel could have a greater benefit than clopidogrel alone in prevention of vascular events with potentially higher bleeding riskASA 75 mg/d + clopidogrel 75 mg/d vs placebo + clopidogrel 75 mg/d*N* = 7599, placebo + clopidogrel: mean age 66.1 years, 54% older than 65 years. ASA + clopidogrel: mean age 66.5 years, 56% older than 65 years. Subgroup analysis age ≥ 65 years18 monthsPrimary outcomes: composite of ischaemic stroke, myocardial infarction, vascular death or rehospitalisation for an acute ischaemic event. Secondary outcomes: Individual and various combinations of each of the outcomes forming the primary endpoint, any death, any strokeEAFT 1993 \[[@CR34]\]RCTTo assess the preventive benefit of anticoagulation or ASA in patients with recent transient ischaemic attack or minor ischaemic strokeASA 300 mg/d vs OAC INR 2.5--4.0 vs placebo*N* = 1007, OAC: mean age 71 years. 80% older than 65 years. ASA: mean age 73 years, 84% older than 65 years. Placebo: mean age 73 years, 84% older than 65 years2.3 yearsPrimary outcomes: death from vascular disease, non-fatal stroke (including haemorrhage), non-fatal myocardial infarction or systemic embolism. Secondary outcomes: death from all causes, all strokes, major thromboembolic eventsHuynh 2001 \[[@CR36]\]RCTTo test the hypothesis that moderate-intensity warfarin either alone or in combination with low-dose ASA will be more effective than ASA alone for the secondary prevention of coronary events in patients with previous CABGASA 80 mg/d + placebo, warfarin INR 2--2.5 + placebo, ASA 80 mg/d + warfarin INR 2--2.5*N* = 135, ASA + placebo: mean age 68, 61% older than 65 warfarin + placebo: mean age 67, 57% older than 65, ASA + warfarin: mean age 66, 53% older than 65 years. Subgroup analysis age ≥ 65 years12 monthsPrimary outcomes: composite end point of any-cause death, myocardial infarction, unstable angina requiring a new hospitalization. Secondary outcome: performance of reperfusion procedure (either percutaneous or open chest)Ikeda 2014 \[[@CR35]\]RCTTo determine whether daily low-dose ASA reduces the incidence of cardiovascular events in older Japanese patients with multiple atherosclerotic risk factorsASA 100 mg/d vs control*N* = 14,464, ASA: mean age 70.6, 82% older than 65. Control: mean age 70.5, 81% older than 655.02 yearsPrimary outcome: composite of death from cardiovascular causes, non-fatal stroke and non-fatal myocardial infarction. Secondary outcomes: composite of primary outcomes + TIA, angina pectoris and arteriosclerotic disease requiring surgery or intervention; death from cardiovascular causes, non-fatal stroke, non-fatal myocardial infarction, TIA, angina pectoris, arteriosclerotic disease requiring surgery or intervention, serious extracranial haemorrhageKjeldsen 2000 (HOT) \[[@CR31]\]RCTTo study the relationship between three levels of target diastolic blood pressure and cardiovascular events in hypertensive patients and to examine the effects of 75 mg ASA daily versus placeboASA 75 mg/d*N* = 18,790; men: mean age 60.8 years, 28% older than 65 years. Women: mean age 62.3 years, 36% older than 65 years. Subgroup analysis age ≥ 65 years3.8 yearsMajor CV events, MI, Stroke CV mortality, total mortalityLiu 2014 \[[@CR47]\]RCTTo compare the therapeutic warfarin and ASA efficacies for treatments of atrial fibrillation complicated with stable coronary heart diseaseWarfarin INR 1.6--2.5, ASA 100 mg/d*N* = 101, warfarin: mean age 84.8 years, ASA: mean age 84.4 years. 100% older than 65 years2 yearsPrimary outcome: ischaemic stroke, systemic embolism. Secondary outcomes: non-fatal myocardial infarction and all causes of deathOgawa 2008 \[[@CR33]\]RCTTo examine the efficacy of low-dose ASA for the primary prevention of atherosclerotic events in patients with type 2 diabetesASA 81--100 mg/d vs control*N* = 2539, mean age 65 years. ASA: 50% older than 65 years. Non-ASA group: 46% older than 65 years. Subgroup analysis age ≥ 65 years4.37 yearsPrimary outcomes: Any atherosclerotic event (composite endpoint of sudden death, death from coronary, cerebrovascular, and aortic causes, non-fatal acute myocardial infarction, unstable angina, newly developed exertional angina, non-fatal ischaemic and haemorrhagic stroke, transient ischaemic attack, non-fatal aortic and peripheral vascular disease). Secondary outcomes: each primary endpoint and combinations of primary endpoints, death from any causeSilagy 1993 \[[@CR32]\]RCTTo investigate the incidence of adverse effects resulting from the use of regular low-dose ASA in an otherwise healthy elderly populationASA 100 mg/d vs placebo*N* = 400, mean age 73 years, 100% older than 65 years12 monthsAdverse events (gastrointestinal symptoms, gastrointestinal bleeding, easy bruising, nose bleeds), haematologic parametersUchiyama 2016 \[[@CR50]\]RCTTo evaluate the effect of ASA on the risk of stroke and intracranial haemorrhage in the Japanese Primary Prevention Project.ASA 100 mg/d vs control*N* = 14,464, ASA: mean age 70.6 years, 82% older than 65 years. No ASA: 70.5 years, 81% older than 65 years5.02 yearsPrimary outcomes: composite of death from cardiovascular causes (including fatal myocardial infarction, fatal stroke, and other cardiovascular death), non-fatal stroke and non-fatal MI. Secondary outcomes: composite of the same events as the primary end points plus TIA, angina pectoris and atherosclerotic disease requiring surgery or intervention. Death from cardiovascular disease, death from nonvascular causes, non-fatal stroke, non-fatal MI, TIA, angina pectoris, atherosclerotic disease requiring surgery or intervention, serious extracranial haemorrhage requiring transfusion or hospitalization.Wiviott 2007 \[[@CR51]\]RCTTo compare prasugrel with clopidogrel for the prevention of thrombotic complications in patients with an acute coronary syndrom and scheduled percutaneous coronary interventionPrasugrel 60 mg loading-dose, 10 mg daily maintenance dose vs clopidogrel 300 mg loading-dose, 75 mg daily maintenance*N* = 13,608, mean age 61 years. Subgroup analysis age ≥ 65 years.6--15 monthsPrimary outcomes: composite of death from cardiovascular causes, non-fatal myocardial infarction, or non-fatal stroke. Secondary outcomes: stent thrombosis and a composite of death from cardiovascular causes, non-fatal myocardial infarction, non-fatal stroke, or rehospitalisation due to a cardiac ischaemic event. Safety outcomes: major bleeding not related to coronary-artery bypass grafting, life threatening bleeding not related to coronary-artery bypass grafting, major and minor bleeding*ASA* acetylsalicylic acid, *BID* twice a day, *CABG* coronary artery bypass graft, *CV* cardiovascular, *INR* international normalized ratio, *MI* myocardial infarction, *OAC* oral anticoagulation, *RCT* randomised controlled trial, *TIA* transient ischemic attack Table 4Characteristics of included observational studiesReferenceType of studyAimTreatmentSample size and number of older participantsFollow-upOutcomesBurton 2006 \[[@CR48]\]Regional cohort-studyTo measure the complication rates and adequacy of warfarin control in a cohort of patients with atrial fibrillation managed in primary care and to compare them with published data from controlled trials and community patients with atrial fibrillation not receiving warfarin.ASA, warfarin INR 2--3, no antithrombotic therapy*N* = 601, mean age 77 years. Subgroup analysis age ≥ 75 years.5 yearsAntithrombotic treatment, stroke or TIA, bleeding complications, deathSam 2004 \[[@CR59]\]Community-based observational cohort-studyTo determine the prevalence of warfarin and ASA use in atrial fibrillation.ASA, warfarin, control*N* = 393, men: mean age 72.5 years, women: mean age 79 years.14 yearsASA and warfarin use, bleeding complication, cardiovascular events*ASA* acetylsalicylic acid, *MI* myocardial infarction, *INR* international normalized ratio, *TIA* transient ischaemic attack Table 5Quality appraisal SR/MAAuthor, year'A priori' DesignDuplicate study selection and data extractionComprehensive literature search performedStatus of publication used as an inclusion criterionList of included and excluded studies providedCharacteristics of the included studies providedScientific quality of included studies assessed and documentedScientific quality of included studies used appropriately in formulating conclusionsAppropriate methods to combine the findings of studiesAssessment of the likelihood of publication biasConflict of interest statedAguilar 2005 \[[@CR49]\]✓✓✓**u**✓✓✓✓✓**✗**✓Aguilar 2007 \[[@CR30]\]✓✓✓**u**✓✓✓✓✓**✗**✓Andersen 2008 \[[@CR43]\]✓✓✓**✗**✓✓✓✓**n/a**✓✓Assiri 2013 \[[@CR44]\]✓**u**✓**✗✗**✓**uu**✓**✗**✓Baignent 2009 \[[@CR28]\]✓**✗**✓**✗**✓✓**✗✗**✓**✗**✓Cameron 2014 \[[@CR46]\]✓✓✓✓✓✓**✗✗**✓**✗**✓Coleman 2012 \[[@CR56]\]✓✓✓✗✓✓✓✓✓✓**✗**Connolly 2013 \[[@CR61]\]✓✓**✗**✓✓✓**✗✗**✓**✗✗**Cooper 2006 \[[@CR42]\]✓**✗**✓**✗✗**✓**✗u✗✗✗**Dogliotti 2014 \[[@CR41]\]✓✓✓**✗✗**✓**✗**✓**✗✗**✓Gandhi 2015 \[[@CR54]\]✓✓✓✓✓✓✓**u**✓✓✓Halkes, 2008 \[[@CR56]\]✓**n/an/a✗**✓✓**✗✗**✓**✗**✓Hart 1999 \[[@CR39]\]✓✓✓**✗✗**✓**✗u**✓**✗✗**Hart 2007 \[[@CR40]\]✓✓✓✓✓✓✓✓✓**✗**✓He 1998 \[[@CR29]\]✓✓**✗✗**✓✓**✗✗**✓**✗**✓Leonardi-Bee 2005 \[[@CR55]\]✓**n/a**✓✓✓✓✓✓**✗✗**✓Lin 2015 \[[@CR57]\]✓✓✓✓✓✓✓**✗✗**✓✓Lip 2006 \[[@CR45]\]✓**✗**✓**✗✗**✓**✗u**✓✓✓Segal 2000 \[[@CR38]\]✓✓✓**✗**✓✓✓✓✓**✗**✓Taylor 2001 \[[@CR37]\]✓**u**✓✓**✗**✓**u**✓✓✓✓Warkentin 2012 \[[@CR57]\]✓✓✓**u**✓✓✓✓**n/a**✓Zhou 2012 \[[@CR52]\]✓✓✓✓✓✓✓✓✓✓✓ Table 6Quality appraisal RCTReferenceRandom sequence generationAllocation concealmentBlinding of participants/personnelBlinding of outcome assessmentIncomplete outcome dataSelective ReportingOther biasBritton 1987 \[[@CR58]\]LRLRLRLRLRLRURDiener 2004 (MATCH) \[[@CR53]\]LRLRURURLRLRLREAFT 1993 \[[@CR34]\]LRLRHRLRLRLRURHuynh 2001 \[[@CR36]\]URURLRURLRLRHRIkeda 2014 \[[@CR35]\]LRLRHRLRLRLRLRKjeldsen 2000 \[[@CR31]\]LRURURURLRLRHRLiu 2014 \[[@CR47]\]URURHRURLRLRLROgawa 2008 \[[@CR33]\]LRLRHRLRLRHRURSilagy 1993 \[[@CR32]\]URURURURLRLRLRUchiyama 2016 \[[@CR50]\]LRLRHRLRURLRLRWiviott 2007 \[[@CR51]\]URURURURLRLRLRNote: *HR* high risk, *LR* low risk, *UR* unclear risk Table 7Quality appraisal OSReferenceStudy addressed a clearly focused issueAuthors used an appropriate method to answer their questionCases/cohort were/was recruited in an acceptable wayControls were selected in an acceptable wayThe exposure was accurately measured to minimize biasThe outcome was accurately measured to minimize biasThe authors identified all important confounding factorsThe follow up of subjects was complete enoughThe follow up of subjects was long enoughResults can be applied to the local populationSam 2004 \[[@CR59]\]✓✓✓✓✓**✗✗**✓✓**✗**Burton 2006 \[[@CR48]\]✓✓✓✓✓**✗✗**✓✓✓Note: ✓: yes, **✗**: no Table 8Quality, strength and evidence-base of the developed recommendationsIndicationRecommendationsStrength of the recommendationQuality of the evidenceEvidence basePrimary prevention CVD (ASA not recommended)It is suggested to discontinue ASA for primary prevention of CVD in adults without diabetes because there is uncertainty about the risk/benefit ratio: The risk of haemorrhagic stroke, major gastrointestinal and extracranial bleeds may be increased, there is less confidence regarding its benefits in decreasing vascular events in adults aged 65 and older.WeakLow\[[@CR28]--[@CR35]\]ASA in the secondary prevention of CVDNo stop recommendation developed\[[@CR36]\]ASA in the primary prevention of stroke\
a) with AF\
b) without AFWith AF: It is suggested to discontinue ASA for the primary prevention of stroke in older adults with atrial fibrillation (including adults older than 75 years) and consider the use of oral anticoagulants instead. Oral anticoagulants are more beneficial than ASA in preventing cardiovascular events and these benefits appear to apply to older people, while the risk of bleeding appears to be similar for both treatments. Without AF: No stop recommendation developedWeakLowWith AF: \[[@CR30], [@CR37]--[@CR49], [@CR56]\] Without AF: \[[@CR50]\]ASA in the secondary prevention of stroke\
a) with AF\
b) without AFNo recommendation developedWith AF: \[[@CR34], [@CR39], [@CR40]\] Without AF: \[[@CR52]\]ADP-receptor inhibitors in secondary prevention of cardiovascular diseaseIt is recommended to discontinue ASA in adults at high-risk of vascular events with recent transient ischaemic attack or ischaemic stroke who are also taking clopidogrel and who do not have another indication for dual therapy (e.g. first year after acute coronary syndrome, first year after elective drug eluting coronary stenting, aortic valve replacement, carotid stenting or complications of severe lower limb ischaemia despite ASA therapy) because the combination of ASA and clopidogrel compared with clopidogrel alone increases the risk of bleeding complications and may not be beneficial in reducing vascular events, especially in the subgroup of adults aged 65 years or older.StrongModerate\[[@CR51], [@CR52]\]ADP- receptor inhibitors in the secondary prevention of stroke and/or transient ischemic attackNo recommendation developed\[[@CR52]--[@CR54]\]Dipyridamol in the secondary prevention of strokeNo recommendation developed\[[@CR55], [@CR56]\]Note: *MA* meta-analysis, *RCT* randomised controlled trial, *SR* systematic review Table 9Characteristics of participants in included SR/MAReferenceSetting/country/ethnicityMale sexAgeComorbidityNumber of coincident medicationsFunctional status/Frailty levelCognitive statusAguilar 2005 \[[@CR49]\]Denmark, Spain, USA62%Mean age 70 yearsNot reportedNot reportedNot reportedNot reportedAguilar 2007 \[[@CR30]\]Asia, Austria, Denmark, Greece, Netherlands, South America, South Africa, Spain, USARanged from 45 to 66%Mean age 64--75 yearsNot reportedNot reportedNot reportedNot reportedAndersen 2013 \[[@CR43]\]Not reportedNot reportedMean age 63.3--81.5 yearsMost of the participants had at least one risk factor for cerebral embolism: previous MI, hypertension, diabetes mellitus, heart failure and/or strokeNot reportedNot reportedNot reportedAssiri 2013 \[[@CR44]\]Not reported58.7%Mean age 71 yearsNot reportedNot reportedNot reportedNot reportedBaigent 2009 \[[@CR28]\]Asia, Italy, UK, USANot reportedSubgroup ≥65 yearsNot reportedNot reportedNot reportedNot reportedCameron 2014 \[[@CR46]\]America, Asia, Canada, Denmark, Japan, UK,Not reportedMean age 62--83 yearsPrior stroke 3%--55%Not reportedNot reportedNot reportedColeman 2012 \[[@CR56]\]Denmark, France, Italy, Japan, Netherlands, Spain, USARanged from 41%--100%Mean age 65--75 yearsNot reportedNot reportedNot reportedNot reportedCooper 2006 \[[@CR42]\]Asia, Australia, Canada, Denmark, Italy, Japan, Netherlands, Spain, Sweden, USARanged from 32%--100%Mean age 64--80.5 yearsPrevious stroke 0--100%Not reportedNot reportedNot reportedConnolly 2013 \[[@CR61]\]Japan, Sweden, USA41%Mean age 57 years, subgroup ≥70 yearsNot reportedNot reportedNot reportedNot reportedDogliotti 2014 \[[@CR41]\]Canada, Japan, UK, USARanged from 46 to 100%Mean age 64--83 yearsHypertension 31.5--90.5%, diabetes mellitus 4--40%, previous myocardial infarction 8.6--19%, heart failure 5--69.5%, previous TIA/stroke 3.7--70%Not reportedNot reportedNot reportedGandhi 2015 \[[@CR54]\]France, Italy, UK43%Mean age 82.2 yearsHypertension 99%, dyslipidemia 52%, coronary heart disease 47%, diabetes mellitus 24%, atrial fibrillation 18%, chronic kidney disease 8.1%, previous myocardial infarction 13%Not reportedNot reportedNot reportedHalkes 2008 \[[@CR56]\]Canada, France, USARanged from 63 to 64%Mean age 65 yearsHypertension 58%, diabetes mellitus 16--17%, ischaemic heart disease 25%Not reportedNot reportedNot reportedHart 2007 \[[@CR40]\]China, Japan, USA75%Mean age 71 yearsNot reportedNot reportedNot reportedNot reportedHart 1999 \[[@CR39]\]Canada, UK, USARanged from 62 to 71%Mean age 69--71 yearsHypertension 45--46%, previous TIA/stroke 20--40%Not reportedNot reportedNot reportedHe 1998 (JAMA) \[[@CR29]\]Australia, Canada, Denmark, France, Sweden, UK. USA, 99% white86%Mean age 59, subgroup ≥64 yearsHypertension 24%, hyperlipidaemia 11%, smoking 21%Not reportedNot reportedNot reportedLeonardi-Bee 2005 \[[@CR55]\]Canada, France, Italy, Spain, USA60%Mean age 65.4Not reportedNot reportedNot reportedNot reportedLiang Lin 2015 \[[@CR63]\]Asia, Canada, China, Denmark, Hong Kong, Israel, Japan, Netherlands, Spain, Sweden, UK, USANRSs 56%, RCTs 62%Mean Age 71.5 years, subgroup-analysis age ≥ 75 yearsHypertension 17--94%, chronic heart failure 1--70%, diabetes mellitus 3--45%, prior TIA/stroke 3--55%Not reportedNot reportedNot reportedLip 2006 \[[@CR45]\]Canada, Denmark, Italy, Netherlands, USANot reportedMean age 64--80 yearsNot reportedNot reportedNot reportedNot reportedSegal 2000 \[[@CR38]\]Canada, Denmark, Netherlands, Sweden, USARanged from 24%--100%Mean age 66--80 yearsDiabetes mellitus 8%--32%, congestive heart failure 9%--71%, hypertension 32%--58%Not reportedNot reportedNot reportedTaylor 2001 \[[@CR37]\]Denmark, Italy, Netherlands, USANot reportedMean age 64--80 yearsNot reportedNot reportedNot reportedNot reportedWarkentin 2012 \[[@CR57]\]Canada, Denmark, Greece, UK, Spain, USARanged from 47 to 89%Mean age 62--83 yearsNot reportedNot reportedNot reportedNot reportedZhou 2012 \[[@CR52]\]Canada, USARanged from 58.2--89.4%Mean age 61.7--71 years, subgroup-analysis age ≥ 65 yearsNot reportedNot reportedNot reportedNot reportedNote: *NRS* Numerical Rating Scale, *RCT*: randomized controlled trial, *TIA*: transient ischaemic attack Table 10Characteristics of participants in included RCTsReferenceSetting/country/ethnicityMale sexAgeComorbidityNumber of coincident medicationsFunctional status/frailty levelCognitive statusBritton 1987 \[[@CR58]\]SwedenASA: 67%, placebo: 58%Mean age 68 years, subgroup analysis age ≥ 68 yearsASA/placebo: hypertension 48%/45%, diabetes mellitus 15%/18%, smoking 48%/57%, hyperlipidaemia 2%/3%, angina 20%/15%, myocardial infarction 11%/9%, heart failure 15%/17%, atrial fibrillation 6%/8%, claudication 9%/8%, previous TIA 8%/8%, previous cerebral infarction 6%/6%, previous other strokes 5%/5%Not reportedCapable of walking by themselves and without aphasia 61%, severely disabled 39%Not reportedDiener 2004 \[[@CR53]\]28 countriesPlacebo: 63%, intervention: 63%Placebo + clopidogrel: mean age 66.1 years, 54% older than 65 years. ASA + clopidogrel: mean age 66.5 years, 56% older than 65 years, subgroup analysis age ≥ 65 yearsPlacebo + clopidogrel/ASA + clopidogrel: hypertension 78%/78%, diabetes mellitus 68%/68%, hypercholesterinaemia 57%/56%, smoking 47%/48%, previous ischaemic stroke 26%/27%, previous TIA 19%/19%, previous myocardial infarction 5%/5%, angina pectoris 12%/13%, symptomatic peripheral arterial disease 10%/10%Not reportedNot reportedNot reportedEAFT 1993 \[[@CR34]\]IsraelOAC: 55%, ASA: 59%, placebo: 53%OAC: mean age 71 years, 80% older than 65 years. ASA: mean age 73 years, 84% older than 65 years, placebo: mean age 73 years, 84% older than 65 yearsWarfarin/ASA/placebo: Multiple strokes in the year prior to randomisation 19%/22%/24%, hypertension 43%/49%/47%, diabetes mellitus 12%/13%/13%, hypercholesterinaemia 12%/10%/7%, smoking 19%/20%/18%, angina pectoris 11%/11%/11%, myocardial infarction 7%/7%/9%, congestive heart failure 8%/11%/12%, minor stroke 8%/8%/6%Not reportedNot reportedNot reportedHuynh 2001 \[[@CR36]\]CanadaASA + placebo: 82.2%, warfarin + placebo: 86.4%, ASA + warfarin: 70.7%ASA + placebo: mean age 68 years, 61% older than 65 years. Warfarin + placebo: mean age 67 years, 57% older than 65 years.\
ASA + warfarin: mean age 66 years, 53% older than 65 years, subgroup analysis age ≥ 65 yearsASA + placebo/warfarin + placebo/warfarin + ASA: hypertension 34.8%/37.8%/38.6%, prior myocardial infarction 56.5%/62.2%/72.7%, current smoking 17.8%/31.1%/20.5%, hyperlipidaemia 43.5%/62.2%/68.2%, diabetes mellitus 17.4%/15.6%/25%ASA + placebo/warfarin + placebo/warfarin + ASA: β-blockers 71.7%/57.8%/70.5%, calcium antagonists 52.2%/55.6%/54.5%, nitrates 63%/64.4%/75%, lipid-lowering agents 37%/42.2%/36.4%, ACE inhibitors 15.3%/35.6%/22.7%, antiarrhythmic agents 2.2%/6.8%/4.6%, diuretics 11%/26.7%/34.1%Not reportedNot reportedIkeda 2014 \[[@CR35]\]JapanASA 42.3%, control 42.4%ASA: mean age 70.6 years, 82% older than 65 years. Control: mean age 70.5 years, 81% older than 65 yearsASA/control: BMI \>25 36.6%/35.9%, hypertension 84.9%/84.8%, dyslipidaemia 72%/71.8%, diabetes mellitus 33.9%/33.9%, smoking 13.3%/12.9%Not reportedNot reportedNot reportedKjeldsen 2000 (HOT) \[[@CR31]\]26 countries53%Men: mean age 60.8 years, 28% older than 65 years. Women: mean age 62.3 years, 36% older than 65 years, subgroup analysis age ≥ 65 yearsMen/women: smoking 21.2%/10%, diabetes mellitus 7.8%/8.2%, previous cardiovascular disease 9.8%/7.4%Men/women: calcium antagonists 45.2%/37.9%, β-blockers 28.3%/28.2%, ACE-inhibitors 39.3%/37.2%, diuretics 29.8%/36.4%Not reportedNot reportedLiu 2014 \[[@CR47]\]ChinaWarfarin: 60.8%, ASA: 60.0%Warfarin: mean age 84.8 years. ASA: mean age 84.4 years, 100% older than 65 yearsWarfarin/ASA: hypertension 39.2%/38%, diabetes mellitus 21.6%/22%, smoking 25.5%/24%, previous myocardial infarction 15.7%/14%, angina pectoris 84.3%/86%Warfarin/ASA: β-blockers 7.8%/6%, statins 11.2%/16%, ACE-inhibitors or ARB 9.8%/12%Not reportedNot reportedOgawa 2008 \[[@CR33]\]JapanASA: 56%, non-ASA: 53%ASA: mean age 65 years, 50% older than 65 years. NonASA group: mean age 64 years, 46% older than 65 years, subgroup analysis age ≥ 65 yearsASA/non-ASA: smoking 23%/19%, hypertension 59%/57%, dyslipidaemia 54%/52%, diabetes mellitus 100%/100%ASA/non-ASA: sulfonylureas 58%/56%, α-glukosidase-inhibitors 33%/32%, biguanides 13%/15%, insulin 13%/13%, thiazolidines 5%/5%, calcium antagonists 35%/34%, angiotensin-II antagonists 21%/21%, ACE-inhibitors 14%/15%, β-blockers 6%/7%, α-blockers 4%/3%, statins 26%/26%Not reportedNot reportedSilagy 1993 \[[@CR32]\]Australia, Germany, USAASA: 48.6%, placebo: 49.6%Mean age 73 years, 100% older than 65 yearsASA/placebo: smoking 4.5%/7.1%Not reportedNot reportedNot reportedUchiyama 2016 \[[@CR50]\]JapanASA: 42.3% no ASA: 42.4%ASA: mean age 70.6 years, 82% older than 65 years. No ASA: 70.5 years, 81% older than 65 yearsASA/no ASA: hypertension 84.9%/84.8%, dyslipidaemia 72%/71.8%, diabetes mellitus 33.9%/33.9%, BMI \>25 36.6%/35.9%, smoking 13.3%/12.9%Not reportedNot reportedNot reportedWiviott 2007 \[[@CR51]\]30 countriesPrasugrel: 75%, clopidogrel 73%Mean age 61 years, 13% older than 75 years, subgroup analysis age ≥ 65 yearsPrasugrel/clopidogrel: hypertension 64%/64%, hypercholesterolemia 56%/56%, diabetes mellitus 23%/23%, smoking 38%/38%, previous myocardial infarction 18%/18%, previous CABG 8%/7%Prasugrel/clopidogrel: heparin 66%/65%, LMWH 9%/8%, bivalirudin 3%/3%, glycoprotein IIb/IIIa--receptor antagonist 54%/55%, ACE inhibitors 76%/75%, β-blockers 88%/88%, statin 92%/92%, calcium antagonists 18%/17%, ASA 99%/99%Not reportedNot reportedNote: *ASA* acetylsalicylic acid, *BMI* Body Mass Index, *CABG* coronary artery bypass graft, *LMWH* low molecular weight heparin, *OAC* oral anticoagulation, *TIA* transient ischaemic attack Table 11Characteristics of participants in included observational studiesReferenceCountryMale sexAgeComorbidityNumber of coincident medicationsFunctional status/frailty levelCognitive statusBurton 2006 \[[@CR48]\]Scotland51%Mean age 77 years, subgroup analysis age ≥ 75 yearsNot reportedNot reportedNot reportedNot reportedSam 2004 \[[@CR59]\]USA49.8%Men: mean age 72.5 years. Women: mean age 79 years, 100% older than 65 yearsASA/warfarin/none: congestive heart failure 14%/22%/65%, previous myocardial infarction 20%/18%/62%, stroke 25%/28%/46%, diabetes mellitus 25%/23%/53%, hypertension 21%/21%/58%, alcohol use 19%/26%/55%Not reportedNot reportedNot reportedNote: *ACE* angiotensin-converting-enzyme, *ASA* acetylsalicylic acid, *AT* Angiotensin, *NSAID* nonsteroidal anti-inflammatory drugs

Data extraction and quality appraisal {#Sec6}
-------------------------------------

Data extraction and quality appraisal were performed using piloted forms. One reviewer did data extraction and quality appraisal and a second reviewer checked the forms for completeness and accuracy. A third reviewer was used in cases of disagreement. Four reviewers (AR, CS, MM, MK) participated at this stage of the SR. Data extracted included the specific drugs and dosages, study methods, time to follow-up, characteristics of the participants, outcomes and results. The quality of the included studies was assessed using specifically validated assessment tools for each type of study design: for SR and MA the AMSTAR appraisal tool \[[@CR20], [@CR21]\] and for clinical trials the Cochrane Collaboration's tool for assessing risk of bias \[[@CR22]\]. For observational studies a selection of questions from the critical appraisal skills programme (CASP) was used \[[@CR23], [@CR24]\].

Development of recommendations {#Sec7}
------------------------------

A document containing a summary of all included studies, emphasising the risks and benefits of PAI was developed. This document and the quality of the study provided the basis for the development of recommendations on the discontinuation of PAI in older adults with cerebrovascular disease, peripheral artery occlusive disease, and coronary disease. Recommendations were judged regarding strength and quality of the evidence using the Grading of Recommendations Assessment Development and Evaluation (GRADE) methodology \[[@CR25]--[@CR27]\]. The final recommendations were worded following a standardised scheme clarifying strength and quality. Four reviewers (ARG, AS, IK, MM) were involved in the development and approval of the recommendations.

Results {#Sec8}
=======

Literature search and inclusion of studies {#Sec9}
------------------------------------------

Figure [1](#Fig1){ref-type="fig"} displays the identification process of studies for inclusion in the SR in a PRISMA flow-chart. Searches 1, 2 and 3a were performed. The research team decided not to perform search 3b for the reasons described above.Fig. 1Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram

There were 964 references identified in the electronic databases during search 1 and 2. After the exclusion of all duplicates, a total of 853 references remained. Through other sources 1532 additional records were identified leading to a total number of 2385 screened records.

Out of those, 403 were identified and selected for full text evaluation, which led to the exclusion of 368 studies. Only 35 articles published between 1987 and 2016 met all inclusion criteria. A list of excluded studies along with the reason for exclusion is available from the authors upon request. The most frequent reason for exclusion was not meeting our age group target.

Among the included studies, there were 22 SR and MA, 11 RCT, and 2 OS. An overview of the main characteristics and quality of the included studies is presented in Tables [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"}, [4](#Tab4){ref-type="table"}, [5](#Tab5){ref-type="table"}, [6](#Tab6){ref-type="table"}, [7](#Tab7){ref-type="table"}, [8](#Tab8){ref-type="table"}, [9](#Tab9){ref-type="table"}, [10](#Tab10){ref-type="table"} and [11](#Tab11){ref-type="table"}. PAI were tested for the following indications: ASA in primary \[[@CR28]--[@CR35]\] and secondary prevention of cardiovascular disease (CVD) \[[@CR36]\], ASA in the primary and secondary prevention of stroke in patients with and without AF \[[@CR30], [@CR34], [@CR37]--[@CR50]\]ADP-receptor inhibitors in secondary prevention of cardiovascular events \[[@CR51], [@CR52]\] and stroke/TIA \[[@CR52]--[@CR54]\], and dipyridamol in secondary prevention of stroke \[[@CR55], [@CR56]\]. Regarding the demographics of the sample, the mean age of participants in the included studies ranges between 57 to 84.6 years. This wide range is due to ten \[[@CR28], [@CR29], [@CR31], [@CR33], [@CR36], [@CR51], [@CR52], [@CR56], [@CR57]\] studies that were included because of a subgroup analysis of people aged above 65 years despite a mean age below the threshold. Polypharmacy was not assessed in any of our included studies. None of the included papers reported on the outcomes quality of life, hospitalisation and life expectancy. Information on the presence of comorbidities was reported by 26 of the included studies, mostly consisting of the presence of cardiovascular risk factors or cardiovascular diseases such as stroke and TIA. Coincident medications were declared in 7 of 40 included references. Frailty was only reported by one study \[[@CR58]\] and cognitive status by none (see Tables [9](#Tab9){ref-type="table"}, [10](#Tab10){ref-type="table"} and [11](#Tab11){ref-type="table"}).

Effectiveness and safety of PAI {#Sec10}
===============================

ASA in the primary prevention of CVD {#Sec11}
------------------------------------

Three SR/MA \[[@CR28]--[@CR30]\] and five RCT \[[@CR31]--[@CR35]\] were included, which examined the primary prevention of CVD. Tha MA of Baigent et al. \[[@CR28]\] detected an insignificant reduction in the occurrence of a composite endpoint of serious vascular events including myocardial infarction, stroke, or death from a vascular cause (including sudden death, pulmonary embolism, haemorrhage) in the subgroup of participants older than 65 years (RR 0.88; 95% CI: 0.77--1.01). Even in the complete study group, the benefit of ASA with an absolute risk reduction (ARR) of 0.06% per year for serious vascular events was very low (number needed to treat (NNT) = 1666 per year). Moreover, there was no difference in vascular or all cause mortality between the ASA group and the placebo group (0.19% vs. 0.19% per year; *p* = 0.7), whereas the risk of major gastrointestinal and extracranial bleeds increased under a treatment with ASA (0.10% vs. 0.07% per year, *p* ≤ 0.0001) (secondary endpoints and adverse effects not calculated for older subgroup).

The study of Kjeldsen et al. (2000) with 18,790 participants \[[@CR31]\] revealed a significant relative risk reduction in the occurrence of myocardial infarction in the subgroup of participants ≥65 years (RR 0.62; 95% CI: 0.38--0.98; *p* = 0.04), but the relative risk of major cardiovascular events was not significantly reduced in the age group ≥65 years (RR 0.92; 95% CI: 0.74--1.15; *p* = 0.47).

The clinical trial of Ikeda et al. (2014) \[[@CR35]\] including 14,464 adults with a mean age of 70 years analysed the impact of ASA on the risk of cardiovascular events in older Japanese patients with multiple atherosclerotic risk factors in comparison to placebo. The primary endpoint of this study was a composite of death from cardiovascular causes (myocardial infarction, stroke, and other cardiovascular causes), nonfatal stroke (ischemic or haemorrhagic), and nonfatal myocardial infarction. Overall, no significant difference in the occurrence of the composite endpoint was observed between the two groups (hazard ratio (HR): 0.94; 95% CI: 0.77--1.15; *p* = 0.54). Moreover, in comparison to the placebo group, the treatment with ASA was associated with a significant increased risk of extracranial haemorrhage requiring transfusion or hospitalization (HR for ASA: 1.85 (95% CI: 1.22--2.81); *p* = 0.004), absolute risk increase 0.35, number needed to harm 286).

Concerning the risk of bleeding in the primary prevention with ASA in older people, the RCT of Silagy et al. \[[@CR32]\] with the oldest participants in this subject area (participants *n* = 400, mean age of participants 73 years) identified more gastrointestinal bleeding events in the ASA group in comparison to the placebo group (3% vs. 0%) with a significant decrease in mean hemoglobin levels (0.33 g/dl vs. 0.11 g/dl; *p* \< 0.05). He et al. (1998) \[[@CR29]\] conducted in a MA a subgroup-analysis of participants above and below 64 years with regard to the risk of haemorrhagic stroke with ASA in comparison to placebo. In the subgroup of participants ≥64 years, the absolute risk difference between the ASA and placebo group was 34 per 10,000 persons (95% CI: 1--66).

The only benefit for ASA was suggested in the RCT of Ogawa et al. (2008) with 2539 participants \[[@CR33]\], (which included only people with diabetes mellitus), where in the subgroup of people older than 65 years the benefit in reducing atherosclerotic events (including fatal or nonfatal ischemic heart disease, fatal or nonfatal stroke, and peripheral arterial disease) was significant (HR 0.68; 95% CI: 0.46--0.99; *p* = 0.047).

ASA in the secondary prevention of CVD {#Sec12}
--------------------------------------

The trial of Huyhn et al. (2001) with 135 participants \[[@CR36]\], analysed the effectiveness of ASA, warfarin, and the combination therapy of ASA and warfarin in participants with prior bypass surgery for the secondary prevention of coronary events. The primary endpoint of this study was a composite of any-cause death, myocardial infarction, or unstable angina requiring a new hospitalization. Monotherapy with ASA as well as ASA plus warfarin were associated with the lowest event rate of the composite endpoint (14.6% warfarin, 11.5% ASA, 11.4% ASA warfarin, *p* = 0.76). For patients aged \>65 years, an overall higher event rate was detected, but ASA monotherapy revealed the lowest event rate (41.7, 34.8% and 36.8 events respectively). HR were not reported in this publication.

ASA in the primary prevention of stroke {#Sec13}
---------------------------------------

Patients with AF: Six SR/MA \[[@CR38]--[@CR40], [@CR42], [@CR44], [@CR49]\] showed conflicting evidence regarding the benefit of ASA compared to placebo in the primary prevention of stroke and all cause mortality. While four of the SR demonstrated no benefit for ASA \[[@CR38], [@CR40], [@CR44], [@CR49]\] (OR for stroke 0.70 (95% CI:0.47--1.07) \[[@CR49]\], 0.56 (95% CI:0.19--1.65) \[[@CR38]\] and RR 0.81 (95% CI:0.65--1.01) \[[@CR40]\] and 1.30 (95% CI:0.96--1.72) \[[@CR44]\] respectively, and for mortality 0.75 (95% CI:0.54--1.04) \[[@CR49]\], 0.87 (95% CI: 0.68--1.12) \[[@CR38]\] and RR 0.86 (95% CI:0.69--1.07) \[[@CR40]\] and 1.28 (95% CI:0.98--1.65) \[[@CR44]\], respectively), two SR \[[@CR39], [@CR42]\] found a significant benefit for stroke, but not for mortality (RR of 0.64 (95% CI: 0.44--0.88) for stroke, no data for mortality \[[@CR42]\], RR 0.78 (95% CI: 0.62--0.98) for stroke and 0.84 (95% CI:0.67--1.05) for mortality \[[@CR39]\]).

In all included trials with ASA \[[@CR38], [@CR40], [@CR42], [@CR44], [@CR49], [@CR59]\] except for one MA \[[@CR39]\], ASA increased the risk of bleeding, especially for gastrointestinal bleeding in comparison to placebo. In the SR of Coleman et al. (2012) \[[@CR60]\], the risk of major gastrointestinal bleeding was three times greater under a treatment with ASA compared with placebo. However, these results did not reach statistical significance (odds ratio (OR) 3.23; 95% CI: 0.56--18.66). Connolly et al. (2013) \[[@CR61]\] also showed an increased risk of a subdural haematoma under a treatment with ASA in comparison to placebo (OR 2.2; 95% CI: 0.6--7.8; *p* = 0.6), but this was not significant.

Eleven SR/MA \[[@CR30], [@CR37]--[@CR46]\], one RCT \[[@CR47]\] and one OS \[[@CR48]\] reported that ASA was less effective in preventing stroke in patients with AF than warfarin. The risk of nonfatal ischemic stroke and systemic embolism was significantly higher with a treatment with ASA compared to warfarin \[[@CR30], [@CR37], [@CR39], [@CR41], [@CR43], [@CR45], [@CR47], [@CR62]\]. Apart from the results of the MA of Dogliotti et al. \[[@CR41]\], there was no significant difference in mortality between the two groups \[[@CR38]--[@CR40], [@CR44], [@CR45], [@CR47]\]. With the exception of six trials \[[@CR30], [@CR42], [@CR45]--[@CR47], [@CR57]\], bleeding events were significantly less frequent in all included studies \[[@CR37]--[@CR41], [@CR43], [@CR44], [@CR48], [@CR60]\] when patients were treated with ASA compared to warfarin. Concerning the use of new oral anticoagulants (NOAC) in older people, ASA were associated with a higher risk of stroke or systemic embolism than NOACs in all included studies \[[@CR41], [@CR44], [@CR46], [@CR63]\]. The MA of Lin et al. (2015) \[[@CR63]\] showed that in ≥75 years old people ASA was less beneficial concerning the prevention of stroke and systemic embolism compared to the dabigatran treated group (dabigatran 110 mg vs. ASA rate ratio: 1.31 (95% CI: 0.84--2.07). Concerning the risk of bleeding inconsistent results were detected. ASA was associated with a decreased risk of bleeding events in comparison to NOACs (apixaban vs. ASA: OR 0.88; 95% CI: 0.31--2.18 \[[@CR41]\]; ASA vs. edoxaban: RR 2.41; 95% CI: 1.02--6.80) \[[@CR44]\]. However, in the SR of Cameron et al. (2014) \[[@CR46]\], ASA increased the risk of major bleeding events (ASA \<100 mg/d vs. edoxaban 30 mg/d: OR 2.27; 95% CI: 1.26--4.1).

Patients without AF {#Sec14}
-------------------

The clinical trial of Uchiyama et al. \[[@CR50]\] with 14,464 participants (mean age 70 years) analysed the impact of ASA on the risk of stroke and intracranial haemorrhage in older Japanese patients without AF in comparison to placebo. Overall, no significant difference in the occurrence of the cumulative rate of fatal or nonfatal stroke was observed between the two groups (HR: 0.92; 95% CI: 0.74--1.16; *p* = 0.51). Five years after randomization, the cumulative rate of fatal or nonfatal stroke in the ASA group was 2.068% (95% CI: 1.75--2.44) as opposed to 2.29% (95% CI: 1.96--2.69) in the placebo group (HR 0.927; 95% CI: 0.741--1.160; *p* = 0.509). Moreover, in comparison to the placebo group, a non-significant reduction of the risk of ischemic stroke or transient ischemic attack was observed in the ASA group (HR 0.783; 95% CI: 0.606--1.012; *p* = 0.061). A treatment with ASA, was associated with a non-significant increase in risk of intracranial haemorrhage in comparison to the placebo group (HR 1.46; 95% CI: 0.956--2.237; *p* = 0.078).

ASA in the secondary prevention of stroke {#Sec15}
=========================================

Patients with AF {#Sec16}
----------------

In these patients, ASA in comparison to placebo showed a higher reduction in secondary than in primary prevention \[[@CR39], [@CR40]\]. The ARR of stroke was between 1.5% (NNT = 67) \[[@CR39]\] and 0.8% per year (NNT= 125) \[[@CR40]\] in the primary prevention trials, and 2.5% per year (NNT = 40) in the secondary prevention trials \[[@CR39], [@CR40]\]. In the EAFT trial with 1007 participants \[[@CR34]\] no significant reduction in the risk of a recurrent stroke by ASA in comparison to placebo was observed (HR 0.86; 95% CI: 0.64--1.15), while the risk of bleeding non-significantly increased under the treatment with ASA (HR 1.3; 95% CI: 0.8--2.15). Warfarin was much more effective than ASA in the secondary prevention of stroke leading to a significant relative risk reduction of 40% in the occurrence of a recurrent stroke (HR 0.60; 95% CI: 0.41--0.87; *p* = 0.008) \[[@CR34]\]. On the other hand, the risk of bleeding was 2.8 fold higher in the warfarin group than in the ASA group (HR 2.8; 95% CI: 1.7--4.8; *p* \< 0.001) \[[@CR34]\].

Patients without AF {#Sec17}
-------------------

One study \[[@CR58]\] including 505 patients with cerebral infarction, minor or major stroke and a mean age of 68 years analysed the secondary prevention of stroke with ASA in comparison to placebo. The primary endpoints of this study were the recurrence of stroke and death. The incidence of stroke recurrence was 6.3% in the ASA treated group and 6.4% in those randomised to placebo. The OR for stroke recurrence and death comparing ASA to placebo was 1.04 (95% CI: 0.68--1.58), reflecting no significant difference between both groups.

ADP-receptor inhibitors in the secondary prevention of CVD {#Sec18}
----------------------------------------------------------

One RCT including 13,608 adults with a mean age of 61 years and a subgroup analysis with people older than 75 years, compared prasugrel and clopidogrel for the management of acute coronary syndromes with scheduled percutaneous coronary intervention \[[@CR51]\]. The primary endpoint of this study was a composite of cardiovascular mortality, non-fatal myocardial infarction, or non-fatal stroke. In all included patients, the composite primary endpoint (as mentioned above) was reached in 12.1% of patients randomised to clopidogrel and 9.9% of those randomised to prasugrel (HR 0.81; 95% CI: 0.73--0.90; *p* ≤ 0.001). Moreover, prasugrel was more effective in reducing the rates of myocardial infarction (9.7% for clopidogrel vs. 7.4% for prasugrel; *p* ≤ 0.001), urgent target-vessel revascularization (3.7% vs. 2.5%; *p* ≤ 0.001), and stent thrombosis (2.4% vs. 1.1%; *p* ≤ 0.001). Several subgroup-analyses were carried out. One subgroup-analysis of participants aged ≥75 years considered the composite endpoint of death from any cause, nonfatal myocardial infarction, nonfatal stroke, or non-CABG-related nonfatal major bleeding. It showed that in the subgroup of patients older than 75 years, there was no benefit of prasugrel in comparison to clopidogrel regarding this composite endpoint (HR 0.99; 95% CI: 0.81--1.21; *p* = 0.92). Another subgroup-analysis examined the combined endpoint of death from any cause, nonfatal myocardial infarction, and nonfatal stroke under a treatment with prasugrel or clopidogrel in three different age groups (\<65 years, 65--74 years, and ≥75 years). In the age group of patients \<65 the combined endpoint (as mentioned above) was reached in 8.1% in the prasugrel group compared to 10.6% in the clopidogrel group (risk reduction 25%, HR not reported). In the age group between 65 years and 74 years the occurrence of the combined endpoint was 10.7% in the prasugrel group and 12.3% in the clopidogrel group (risk reduction 14%, no HR reported). In the age group of participants ≥75 years, the risk reduction attributed to prasugrel in comparison to clopidogrel was the lowest of the considered three age groups (17.2% prasugrel group, 18.3% clopidogrel group, risk reduction of 6%, HR or OR not reported). The MA of Zhou et al. \[[@CR52]\] with 7 trials including 48,248 participants, investigated the risks and benefits of a dual therapy with ASA and clopidogrel vs. monotherapy for the secondary prevention of cardiovascular and cerebrovascular events (see below). The population, included in this MA, were a mixed population. The participants had for example atrial fibrillation, multiple atherothrombotic risk factors, previous coronary artery bypass grafting/PCI or acute coronary syndromes without ST-segment elevation. The combination therapy was non-significantly more effective than the single drug therapy alone in reducing the rate of major cardiovascular events (9% RR reduction; 95% CI: 2--17) when all participants were included. The relative risk of MI was decreased by 14% (RRR 14%; 95% CI: 3--24). Overall, the ARR of major cardiovascular events due to the combination therapy was 1.06 with a NNT of 83. On the other hand, the combination therapy resulted in a significant 62% RR increase of major bleeding events (95% CI: 26--108) when compared to single drug therapy. For the subgroup analysis of participants older than 65 years, a comparison between the combination therapy and a monotherapy with ASA was performed. In the older participants (≥65 years), the reduction of major cardiovascular events was marginally significant (≥65 years RR: 0.90; 95% CI: 0.83--0.98), whereas the risk of major bleeding events under a treatment with ASA plus clopidogrel vs. ASA monotherapy was significantly higher (≥65 years: RR: 1.56; 95% CI: 1.29--1.89).

ADP- receptor inhibitors in the secondary prevention of stroke and/or transient ischemic attack {#Sec19}
-----------------------------------------------------------------------------------------------

The MA of Zhou et al. \[[@CR52]\] described above also investigated, the secondary prevention of cardiovascular events, and the secondary prevention of stroke. With regard to this outcome, the greatest reduction was detected in the occurrence of stroke (RR 16%; 95% CI: 1--28).

In the RCT of Diener et al. (2004) with 7599 participants \[[@CR53]\] the benefit to risk ratio did not show the additional clinical value of adding ASA to clopidogrel in high-risk patients with transient ischaemic attack or ischaemic stroke. A subgroup analysis (*n* = 4537) by age (≥65 years) showed that the event rate for clopridogrel plus ASA was 17.4% and for clopidogrel plus placebo 17.7%.

The dual antiplatelet therapy (DAPT) with ASA and clopidogrel was associated with an increased risk of 30-day major stroke, spontaneous MI, all-cause mortality, and combined lethal and major bleeding in the DAPT group compared to monotherapy even in patients who underwent Transcatheter Aortic Valve Implantation (TAVI) (OR 1.88; 95% CI: 1.00--3.56). The biggest increase was detected in the occurrence of lethal and major bleeding events (OR 2.62; 95% CI: 1.29--5.33) \[[@CR54]\].

Dipyridamol (DP) in the secondary prevention of stroke {#Sec20}
------------------------------------------------------

The MA of Leonardi-Bee et al. \[[@CR55]\] with 11,459 participants including a subgroup-analysis of participants older than 65 years identified a non-significant decrease in the reoccurrence of stroke under treatment with DP in comparison to placebo (OR 0.82; 95% CI: 0.68--1.00). In the subgroup of participants ≥65 years the reduction of stroke was non-significant (DP vs. placebo subgroup ≥65 years: OR 0.81; 95% CI: 0.65--1.02). The combination therapy of ASA + DP in comparison to an ASA monotherapy revealed a significant reduction of stroke \[[@CR55], [@CR56]\] (ASA + DP vs. ASA monotherapy: Age ≥ 65 years: OR 0.78; 95% CI: 0.63--0.97) \[[@CR55]\]. There was no difference in mortality between the two treatment groups (ASA + DP vs. ASA: HR 1.01, 95% CI 0.87--1.17) \[[@CR56]\].

Quality appraisal of included studies {#Sec21}
=====================================

SR and MA {#Sec22}
---------

Table [5](#Tab5){ref-type="table"} displays the results of quality appraisal of the SR and MA. One MA \[[@CR52]\] fulfilled all requirements of the AMSTAR appraisal tool. Several quality deficits were detected when evaluating the other studies using the AMSTAR appraisal tool. In all included MA/SR an a priori design was provided. A duplicate study selection and data extraction were missing in the MA/SR of Baigent et al. \[[@CR28]\], Lip et al. \[[@CR45]\] and Cooper et al. \[[@CR42]\]. In the SR/MA of Leonardi-Bee et al. \[[@CR55]\], Taylor et al. \[[@CR37]\], and Assiri et al. \[[@CR44]\] this information was not available. A comprehensive literature search was not performed in the MA/SR of Connolly et al. \[[@CR61]\] and He et al. \[[@CR29]\]. Eleven MA \[[@CR28], [@CR29], [@CR38], [@CR40]--[@CR45], [@CR56], [@CR60]\] did not search for grey literature. Quality appraisal of the included studies was not performed in 10 MA/SR \[[@CR28], [@CR29], [@CR39], [@CR41]--[@CR43], [@CR45], [@CR46], [@CR56], [@CR61]\]. Possible conflicts of interest were not declared in four MA \[[@CR39], [@CR42], [@CR60], [@CR61]\]. All included SR/MA described the characteristics of the included studies. The likelihood of publication bias was presented in seven MA/SR \[[@CR37], [@CR43], [@CR45], [@CR52], [@CR54], [@CR60], [@CR63]\].

RCTs {#Sec23}
----

Table [6](#Tab6){ref-type="table"} displays the results of quality appraisal of the RCTs. An appropriate random sequence generation was used in seven \[[@CR31], [@CR33]--[@CR35], [@CR50], [@CR53], [@CR58]\] of 11 RCTs. In four RCTs \[[@CR32], [@CR36], [@CR47], [@CR51]\], the random sequence was unclear. Allocation concealment was fulfilled in six studies \[[@CR33]--[@CR35], [@CR50], [@CR53], [@CR58]\] and unclear in five studies \[[@CR31], [@CR32], [@CR36], [@CR47], [@CR51]\]. Serious limitations were found in blinding of personnel and participants in five RCTs \[[@CR33]--[@CR35], [@CR47], [@CR50]\], whereas Huynh et al. \[[@CR36]\] and Britton et al. \[[@CR58]\] performed appropriate blinding of personnel and participants. In four RCTs \[[@CR31], [@CR32], [@CR51], [@CR53]\] this remained unclear. The outcomes were unlikely to be influenced by a lack of blinding in five studies \[[@CR33]--[@CR35], [@CR50], [@CR58]\]. The blinding of trials was appropriate in five studies \[[@CR33]--[@CR35], [@CR50], [@CR58]\]. In the remaining studies the blinding outcome was unclear. In the study of Ogawa et al. \[[@CR33]\], a high risk for selective reporting was detected due to a missing representation of adverse events in the subgroup analysis of adults ≥65 years of age. Inclusion and exclusion criteria for participants and the primary outcomes were clearly defined and stated in all studies. In two trials \[[@CR31], [@CR36]\] differences between the treatment groups after randomisation were identified. The loss to follow-up was less than 5% in six trials \[[@CR31], [@CR32], [@CR36], [@CR51], [@CR53], [@CR58]\] whereas the RCT of Ogawa et al. \[[@CR33]\], the EAFT trial \[[@CR34]\] and the clinical trial of Ikeda et al. \[[@CR35]\] had a higher loss to follow-up. In the two other trials \[[@CR47], [@CR50]\] it remained unclear. Conflicts of interests were stated in all RCTs except in two trials \[[@CR31], [@CR34]\]. In the EAFT \[[@CR34]\] trial a high risk for biased selection of participants was detected because all participants who were not eligible for a treatment with warfarin (e.g. due to previous bleeding events) were assigned to the ASA group.

Observational studies {#Sec24}
---------------------

Table [7](#Tab7){ref-type="table"} displays the results of quality appraisal of the OS. In the two included OS \[[@CR48], [@CR59]\] we could not identify important confounding factors due to a lack of information and an undersized database. The results could be influenced by a lack of blinding of personnel and participants in all included studies.

Development of recommendations {#Sec25}
------------------------------

We developed three recommendations which are presented in Table [8](#Tab8){ref-type="table"}. One recommendation was rated as strong with moderate quality of evidence. The two other recommendations were assessed as weak with low quality of evidence. Table [8](#Tab8){ref-type="table"} reports on the main articles, which constitute the evidence base for each recommendation, although all included studies were taken into account for the risk/benefit balance during the review process. The quality appraisal of each RCT included in the SR and MA provided the evidence base for the recommendations. All quality appraisals were considered in assessing the quality of the evidence of the recommendations and are available from the authors upon request. Based on the evaluated evidence we formulated three recommendations. The first recommendation deals with the use of ASA in the primary prevention of CVD and stroke in older people without diabetes. The strength of the recommendation is weak and the quality of the evidence was judged as low. Concerning the primary prevention of CVD and stroke in the elderly with ASA, no benefit could be shown in patients without AF compared to placebo. Moreover, the risk of haemorrhagic stroke \[[@CR28], [@CR29]\], major gastrointestinal \[[@CR28], [@CR32]\] and other extracranial non-fatal bleeds \[[@CR28], [@CR31], [@CR35]\] were significantly increased. In contrast, for people with diabetes mellitus the trial of Ogawa et al. \[[@CR33]\] showed that the greatest benefit of a treatment with ASA in comparison to placebo was detected in the subgroup of participants older than 65 years. Due to this effect, adults with diabetes mellitus were not included in our recommendation. However, a high risk for selective reporting was detected in this study due to a lack of reporting adverse events in the subgroup analysis of adults ≥65 years of age.

Overall, we reached similar conclusions to the Beers criteria for potentially inappropriate medications in older people, which recommend using ASA with caution in adults older than 80 years for primary prevention of CVD \[[@CR64], [@CR65]\].

The second recommendation was developed based on the evidence of MA of Zhou et al. \[[@CR52]\] and the RCT of Diener et al. \[[@CR53]\]. We recommend avoiding the combination of a dual therapy in the secondary prevention of TIA and stroke with clopidogrel and ASA and to consider monotherapy instead. The evidence shows that a dual therapy increases the risks of bleeding complications and is not beneficial in the secondary prevention of vascular events, especially in the subgroup of adults aged 65 years or older. Adults with another indication for dual therapy (see Table [8](#Tab8){ref-type="table"}) must be excluded from this recommendation. Due to the high quality of the evidence base the strength of the recommendation was rated as strong whereas the quality of evidence was downgraded to moderate quality caused by the indirectness of results. This recommendation was similar to the recommendation of the STOPP/START criteria for potentially inappropriate prescribing in older people, which recommends to stop a dual therapy with ASA and clopidogrel for secondary prevention of stroke (expections are: the patient underwent coronary stenting in the previous 12 months or has a high grade symptomatic carotid arterial stenosis) \[[@CR66]\].

The third recommendation is to discontinue the use of ASA for the primary prevention of stroke in older adults with AF (including adults older than 75 years), because current evidence points at an unfavourable risk/benefit ratio for ASA compared to placebo. None of the identified SR demonstrated a benefit regarding mortality, and only two older SR \[[@CR39], [@CR42]\] appear to show a benefit regarding stroke. The most recent and reliable SR including a comprehensive network meta-analysis does not show this benefit \[[@CR44]\]. Instead, the use of a Vitamin K Antagonist should be considered. This recommendation is based on the evidence of eleven SR/MA \[[@CR30], [@CR37]--[@CR41], [@CR46], [@CR57], [@CR63]\] and one clinical trial \[[@CR47]\]. The recommendation was rated as weak and the quality of the evidence as low. The evidence showed a superiority of warfarin in the prevention of cerebrovascular diseases. In regard to the risk of bleeding, contrasting results were found. With the exception of three trials \[[@CR46], [@CR47], [@CR57]\], bleeding events were significantly more frequent when compared to ASA. However, the trial \[[@CR47]\] with the oldest participants suggested a benefit of warfarin over ASA in octogenarians. There were significantly more ischemic strokes and systemic embolism with ASA than with warfarin but there were significantly fewer adverse events (including bleeding) with warfarin than ASA, assuming a safe handling even in adults older than 80 years. The dose of ASA and the target-INR in the included studies were roughly comparable. A major limitation of this recommendation is that the dose of ASA of 300 mg per day (as it was used in several studies) was higher than the usual applied dose.

We were limited to providing three recommendations to stop treatments because of a lack of reliable studies in our age group. In relation to secondary prevention, the recommendations for the use of PAI are mainly based on studies of younger patients, and it is currently unknown whether these recommendations are transferable to older people. Nonetheless, taking current best evidence regarding younger patients into account, it does not seem justified to formulate a stop recommendation for older people.

Discussion {#Sec26}
==========

Our systematic review examined the benefits and risks of the treatment with PAI for the management of cardiovascular, cerebrovascular and peripheral vascular diseases in older people. This systematic review is part of a compilation of systematic reviews on commonly used drugs in older people and aimed to identify the evidence to develop recommendations on when to discontinue the inappropriate use of these medications in older adults. Based on the evaluated evidence we formulated three recommendations.

Our SR has strengths as well as limitations. To the best of our knowledge, this is the first SR that has searched the evidence on the use of PAI specifically amongst older people. We followed a standard methodology as recommended by the Cochrane collaboration and the PRISMA statement, used a predefined step-wise search approach and piloted our search strategy. This systematic search strategy has the advantage that the search strategy is transparent and reproducible and will have utility in assessing the evidence for treatments aimed specifically at older people. Unfortunately, many papers had to be excluded as they did not report on the evidence for treatments in older people reflecting the lack of studies in this age group. An example was the lack of evidence concerning the secondary prevention of stroke and cardiovascular disease with ASA in comparison to placebo. The only study for secondary prevention of CVD, that met our inclusion criteria, was a small study with 132 participants and insignificant results. Current guidelines on recommendations to prescribe ASA in the secondary prevention of CVD and stroke are therefore based on study evidence derived from younger patients \[[@CR67]\]. We do not know whether the benefits shown in these studies are also applicable to older people. There are ongoing studies targeted at filling this evidence gap. The largest of these studies is the ASPREE Trial (study protocol published 2013) \[[@CR68]\], taking place in Australia. It included 16,700 participants aged 70 years and older and aims to analyse the impact of daily low-dose aspirin on cardiovascular disease (heart attack and stroke) in older people. The results of the ASPREE trial are expected to be published in 2018.

Another limitation is that our search strategy resulted in SR and MA with overlapping studies (see additional file [2](#MOESM2){ref-type="media"}). Altogether, 143 studies were included in the SR and MA and out of these studies, 40 studies were counted repeatedly. This probably meant that outcomes from these overlapping studies would be weighted more positively in our analyses compared to studies, which have only been included once. Despite the overlap, we decided to include all SR and MA because they offered additional relevant information.

We included two different types of MA namely standard MA based on head-to-head comparisons and network MA making indirect comparisons. Although the strength of evidence of network MA in general is considered to be weaker than that of standard MA, this would not have led a different conclusion in our SR. It is important to note that due to our methodology we could not take into account the strength of evidence of network MA which is generally weaker.

During the development of our recommendations we weighted the benefits and risks for using platelet aggregation inhibitors in older people \[[@CR19]\]. We did not assess the material for people of other ages and we did not look for possible start recommendations because our study had the specific aim of helping to reduce polypharmacy in older people. The widespread use of ASA contributes significantly to the problem of polypharmacy. \[[@CR69]\]. With the implementation of our recommendations we hope to contribute to a reduction in the treatment with PAI and hence reduce inappropriate polypharmacy. We hope our recommendations will lead to the development of new guidelines specifically addressing the drug treatment of old and multi-morbid adults. We are currently using these recommendations in an electronic decision support tool aimed at reduce polypharmacy in a multicenter, randomised, controlled PRIMA-eDS trial with 3900 patients \[[@CR18]\].

Conclusions {#Sec27}
===========

Based on the evaluated evidence, this systematic review was able to develop three recommendations. The use of ASA for the primary prevention of CVD and the combination therapy of ASA and clopidogrel for the secondary prevention of vascular events in older people may not be justified when the risk-benefit ratio is taken into account. The use of warfarin instead of ASA in older patients with AF may be recommended. To improve the effectiveness and reduce the risks of stroke prevention therapy in older people with AF, the discontinuation of ASA for the primary prevention of stroke should be considered and oral anticoagulants could be used instead (low quality of evidence).

Older patients with multimorbidity and polypharmacy are underrepresented in clinical trials. None of the articles, that we identified, reported on patients with polypharmacy. We were therefore not able to develop recommendations for reducing polypharmacy in patients who are old and with multi-morbidity. The benefits of many treatments for these patient groups are less clear and further good quality studies are needed for example RCTs investigating the individualised assessment of multi-morbid people with polypharmacy (including PAI).

We expect our recommendations in addition with the other recommendations of the PRIMA-eDS trial to contribute to the development of new guidelines specifically addressing the drug treatment of old adults with multi-morbidity.
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AF

:   Atrial fibrillation

AMSTAR

:   Assessment of multiple systematic reviews

ARR

:   Absolute risk reduction

ASA

:   Acetylsalicylic acid

CASP

:   Critical Appraisal Skills Programme

CI

:   Confidence interval

CVD

:   Cardiovascular disease

DAPT

:   Dual- antiplatelet therapy

DARE

:   Database of Abstracts or Reviews of Effects

DP

:   Dipyridamole

GRADE

:   Grading of Recommendations Assessment, Development and Evaluation

HR

:   Hazard ratio

HTA

:   Health Technology Assessment

IPA

:   International Pharmaceutical Abstracts

MA

:   Meta-analysis

NNT

:   Number needed to treat

OR

:   Odds ratio

OS

:   Observational study

PAI

:   Platelet aggregation inhibitors

PICOS

:   Population, intervention, comparison, outcomes and study design

PRIMA-eDS

:   Polypharmacy in chronic diseases: Reduction of Inappropriate Medication and Adverse drug events in older populations by electronic Decision Support

RCT

:   Randomised controlled trial

SR

:   Systematic review

TIA

:   Transient ischaemic attack

VKA

:   Vitamin K Antagonist
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